Compare BLTE & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | CHE |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | 15811 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 2021 | 1994 |
| Metric | BLTE | CHE |
|---|---|---|
| Price | $137.18 | $439.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $198.00 | ★ $501.50 |
| AVG Volume (30 Days) | 104.2K | ★ 223.3K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.84 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | N/A | $6.56 |
| Revenue Next Year | $492.11 | $6.23 |
| P/E Ratio | ★ N/A | $90.82 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $56.68 | $365.21 |
| 52 Week High | $200.00 | $580.50 |
| Indicator | BLTE | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 65.49 |
| Support Level | $103.94 | $423.89 |
| Resistance Level | $172.02 | $457.32 |
| Average True Range (ATR) | 7.11 | 11.19 |
| MACD | -1.16 | 0.74 |
| Stochastic Oscillator | 7.06 | 78.41 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.